UTMB developed the vaccine with biotechnology company Profectus BioSciences, and the vaccine has been tested it in the Galveston (Texas) National Laboratory, the only fully operational Biosafety Level 4 laboratory on an academic campus in the country.
The vaccine — developed by the multidisciplinary team using a nonhuman primate model — employs a virus not harmful to humans called vesicular stomatitis virus that had a part of the Ebola virus inserted into it to trigger an immune response.
“These findings may pave the way for the identification and manufacture of safer, single-dose, high-efficiency vaccines to combat current and future Ebola outbreaks,” said Thomas Geisbert, PhD, UTMB professor of microbiology and immunology. “We are excited at the possibility of helping develop a way to stop this deadly disease. We have a lot of more work to accomplish but it’s important to note that this is a big step.”
More articles on Ebola:
Johns Hopkins Hospital builds Ebola isolation unit
Physician develops Ebola diagnostic tool
Does Ebola planning prepare hospitals for reality of treating patients?
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
